Literature DB >> 12204321

A randomised, controlled trial of fluoxetine in methadone maintenance patients with depressive symptoms.

Angela J Dean1, James Bell, David J Mascord, Gordon Parker, Macdonald J Christie.   

Abstract

BACKGROUND: Depression and antidepressant use are prevalent in methadone maintenance patients (MMPs). However, antidepressant efficacy is not well established in this population. This study examined the efficacy of fluoxetine in improving depressive symptoms and reducing substance use in MMPs.
METHODS: Stabilised MMPs scoring over 21 on the Beck Depression Inventory were randomised to receive fluoxetine or placebo over 12 weeks.
RESULTS: Forty-nine subjects were randomised. In both groups, significant improvements were observed in depression, life functioning, and social impairment over 12 weeks. Poly-drug use improved in completers only. No fluoxetine effects were observed.
CONCLUSIONS: Little evidence supports use of fluoxetine as a treatment for depressive symptoms in MMPs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12204321     DOI: 10.1016/s0165-0327(01)00419-0

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  4 in total

1.  Opioidergic Agents as Antidepressants: Rationale and Promise.

Authors:  Parnika P Saxena; J Alexander Bodkin
Journal:  CNS Drugs       Date:  2019-01       Impact factor: 5.749

Review 2.  Selective serotonin reuptake inhibitors in the treatment of depression, anxiety, and post-traumatic stress disorder in substance use disorders: a Bayesian meta-analysis.

Authors:  Dimy Fluyau; Paroma Mitra; Ankit Jain; Vasanth Kattalai Kailasam; Christopher G Pierre
Journal:  Eur J Clin Pharmacol       Date:  2022-03-05       Impact factor: 2.953

3.  The Role of Opiates in Social Pain and Suicidal Behavior.

Authors:  Benedicte Nobile; Pierre-Eric Lutz; Emilie Olie; Philippe Courtet
Journal:  Curr Top Behav Neurosci       Date:  2020

4.  Does naltrexone treatment lead to depression? Findings from a randomized controlled trial in subjects with opioid dependence.

Authors:  Angela J Dean; John B Saunders; Rod T Jones; Ross M Young; Jason P Connor; Bruce R Lawford
Journal:  J Psychiatry Neurosci       Date:  2006-01       Impact factor: 6.186

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.